Although these proposals do not immediately change the legal status of either substance, they represent important signals for manufacturers, formulators, and regulatory professionals. Understanding what these developments mean is essential for anticipating future regulatory trends.
What ECHA Proposals are
Before a substance is restricted or prohibited under European legislation, it often undergoes a lengthy scientific and regulatory evaluation process. One of the key mechanisms within this process is the proposal for a harmonised classification and labelling (CLH) under the Classification, Labelling and Packaging (CLP) Regulation.
A CLH proposal does not automatically result in new restrictions. Instead, it initiates a scientific assessment that may ultimately lead to a harmonised hazard classification across the European Union. Depending on the outcome, such classifications can have significant consequences for sectors including cosmetics, detergents, and other consumer products.
Recent proposals concerning Climbazole and Benzylhemiformal illustrate how different types of hazard concerns can trigger regulatory scrutiny.
Climbazole
Climbazole is a well-known antifungal ingredient commonly used in anti-dandruff shampoos and scalp-care products. It has been used safely in cosmetic products for many years within the concentration limits established by European cosmetic legislation.
In March 2026, Belgium submitted an intention to propose a harmonised classification for Climbazole as an endocrine disruptor for the environment. The proposal follows a broader assessment of the substance under the REACH Regulation.
Importantly, the concerns identified relate primarily to environmental effects rather than consumer safety. Current evaluations have not concluded that cosmetic uses of Climbazole present an unacceptable risk to consumers when used in accordance with existing regulatory requirements. However, concerns have been raised regarding its potential impact on aquatic ecosystems and its endocrine-disrupting properties in environmental species.
At this stage, Climbazole remains authorised for cosmetic use under the conditions established in the EU Cosmetics Regulation. Nevertheless, the proposal signals increased regulatory attention and may influence future discussions regarding its long-term regulatory status.
For manufacturers relying on Climbazole in anti-dandruff formulations, this is a development worth monitoring closely, even though no immediate reformulation requirements currently exist.
Benzylhemiformal
The situation surrounding Benzylhemiformal is potentially more consequential.
Austria has submitted a proposal for a harmonised classification of Benzylhemiformal as a Category 1B carcinogen. This classification category is used for substances presumed to have carcinogenic potential for humans based on available evidence.
Within the European cosmetics framework, substances classified as carcinogenic, mutagenic, or toxic for reproduction (CMR) are subject to particularly strict regulatory treatment. In many cases, such classifications can lead to prohibition in cosmetic products unless specific conditions are met and a positive safety assessment supports continued use.
As a result, the regulatory implications of a possible Carcinogen Category 1B classification could be substantially greater than those associated with the environmental concerns currently being considered for Climbazole.
It is important to emphasise that the proposal has not yet been adopted. The scientific evaluation process remains ongoing, and any final classification would only take effect after review by ECHA’s Risk Assessment Committee and subsequent regulatory procedures.
What Happens Next?
Both substances will now proceed through the established European regulatory process.
Scientific experts will review the available evidence, stakeholders will have opportunities to provide comments during public consultations, and ECHA’s committees will ultimately issue their opinions. Only after these steps are completed can a final harmonised classification be adopted by the European Commission.
Because this process often takes several years, immediate regulatory changes should not be expected. However, companies should view these proposals as early indicators of possible future developments.
What Should Cosmetic Manufacturers Do?
For most companies, the current priority is awareness rather than action.
Manufacturers using Climbazole should continue monitoring developments and maintain communication with ingredient suppliers regarding future regulatory updates. Companies using Benzylhemiformal may wish to assess potential alternatives and evaluate the strategic implications of a possible future CMR classification.
Regulatory intelligence has become increasingly important in today’s cosmetic market. Early awareness of emerging regulatory trends allows companies to make informed decisions, avoid unexpected reformulation challenges, and maintain compliance in an evolving legislative environment.
